Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

Researchers launch a public immune atlas of pancreatic cancer therapy responses, allowing the public to rapidly link pancreatic cancer immunotherapy trials to immune shifts and outcomes. Imagine ...

Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life ...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...

A new cohort study suggests that Medicaid expansion is associated with a lower mortality risk among patients with pancreatic ...

During the 2026 legislative session, lawmakers have revived or introduced bills aimed at curbing Iowa’s cancer rates. Here’s ...

Researchers from NTU Hospital and Academia Sinica have developed PanMETAI, a breakthrough AI metabolomics platform for early pancreatic cancer diagnosis.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an ...

The return to work was filled with emotion for Carlo Vanzini, the historic voice of Formula 1 in Italy. After difficult ...